Liang-Ping Xia (Liangping Xia)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 16

Top Topics

Body Mass Index

Editorial Comment

Top Venues

British journal of cancer

Cancer medicine

Cancer immunology, immunotherapy : CII

Proceedings of the National Academy of Sciences of the United States of America

This page only lists publications with an associated author ORCID identifier.

Publications

Lin Yang, Jiahong Yi, Wenzhuo He, Pengfei Kong, Qiankun Xie, Yanan Jin, Zhenchong Xiong, Liang-Ping Xia
Death receptors 4/5 mediate tumour sensitivitNot applicably to natural killer cell-mediated cytotoxicity in mismatch repair deficient colorectal cancer. British journal of cancer (2024)
Lin Yang, Jiahong Yi, Wenzhuo He, Pengfei Kong, Qiankun Xie, Yanan Jin, Zhenchong Xiong, Liang-Ping Xia
Death receptors 4/5 mediate tumour sensitivitNot applicably to natural killer cell-mediated cytotoxicity in mismatch repair deficient colorectal cancer. British journal of cancer (2024)
Lin Yang, Jiahong Yi, Wenzhuo He, Pengfei Kong, Qiankun Xie, Yanan Jin, Zhenchong Xiong, Liang-Ping Xia
Death receptors 4/5 mediate tumour sensitivity to natural killer cell-mediated cytotoxicity in mismatch repair deficient colorectal cancer. British journal of cancer 131 (2) (2024)
Lin Yang, Jiahong Yi, Wenzhuo He, Pengfei Kong, Qiankun Xie, Yanan Jin, Zhenchong Xiong, Liang-Ping Xia
Death receptors 4/5 mediate tumour sensitivity to natural killer cell-mediated cytotoxicity in mismatch repair deficient colorectal cancer. British journal of cancer 131 (2) (2024)
Lin Yang, Jiahong Yi, Wenzhuo He, Pengfei Kong, Qiankun Xie, Yanan Jin, Zhenchong Xiong, Liang-Ping Xia
Death receptors 4/5 mediate tumour sensitivity to natural killer cell-mediated cytotoxicity in mismatch repair deficient colorectal cancer. British journal of cancer (2024)
Lin Yang, Jiahong Yi, Wenzhuo He, Pengfei Kong, Qiankun Xie, Yanan Jin, Zhenchong Xiong, Liang-Ping Xia
Correction: Death receptors 4/5 mediate tumour sensitivity to natural killer cell-mediated cytotoxicity in mismatch repair deficient colorectal cancer. British journal of cancer (2024)
Lin Yang, Jiahong Yi, Wenzhuo He, Pengfei Kong, Qiankun Xie, Yanan Jin, Zhenchong Xiong, Liang-Ping Xia
Correction: Death receptors 4/5 mediate tumour sensitivity to natural killer cell-mediated cytotoxicity in mismatch repair deficient colorectal cancer. British journal of cancer (2024)
Lin Yang, Jiahong Yi, Wenzhuo He, Pengfei Kong, Qiankun Xie, Yanan Jin, Zhenchong Xiong, Liang-Ping Xia
Death receptors 4/5 mediate tumour sensitivity to natural killer cell-mediated cytotoxicity in mismatch repair deficient colorectal cancer. British journal of cancer 131 (2) (2024)
Lin Yang, Jiahong Yi, Wenzhuo He, Pengfei Kong, Qiankun Xie, Yanan Jin, Zhenchong Xiong, Liang-Ping Xia
Death receptors 4/5 mediate tumour sensitivity to natural killer cell-mediated cytotoxicity in mismatch repair deficient colorectal cancer. British journal of cancer (2024)
Lin Yang, Jiahong Yi, Wenzhuo He, Pengfei Kong, Qiankun Xie, Yanan Jin, Zhenchong Xiong, Liang-Ping Xia
Death receptors 4/5 mediate tumour sensitivity to natural killer cell-mediated cytotoxicity in mismatch repair deficient colorectal cancer. British journal of cancer 131 (2) (2024)
Chenran Wang, Maohua Huang, Yuning Lin, Yiming Zhang, Jing-Hua Pan, Chang Jiang, Minjing Cheng, Shenrong Li, Wen-Zhuo He, Zhengqiu Li, Zhengchao Tu, Jun Fan, Huhu Zeng, Jiahui Lin, Yongjin Wang, Nan Yao, Tongzheng Liu, Qi Qi, Xiangning Liu, Zhi-Min Zhang, Minfeng Chen, Liang-Ping Xia, Dongmei Zhang, Wen-Cai Ye
ENO2-derived phosphoenolpyruvate functions as an endogenous inhibitor of HDAC1 and confers resistance to antiangiogenic therapy. Nature metabolism (2023)
Wen-Zhuo He, Lei Wang, Chen-Xi Yin, Jia-Hong Yi, Ya-Nan Jin, Chang Jiang, Gui-Fang Guo, Liang-Ping Xia
Regorafenib with or without a programmed cell death protein 1 antibody as third-line treatment for microsatellite stable metastatic colorectal cancer. Cancer medicine (2022)
Yafei You, Chang Jiang, Kunwei Peng, Wenzhuo He, Lei Wang, Yanan Jin, Liang-Ping Xia
The predictive value of body mass index on prognosis and adverse events of cancers treated with immunotherapy: a systematic review and meta-analysis. Cancer immunology, immunotherapy : CII 70 (8) (2021)
Yuan-Zhong Yang, Wan-Ming Hu, Liang-Ping Xia, Wen-Zhuo He
Association between somatic RET mutations and clinical and genetic characteristics in patients with metastatic colorectal cancer. Cancer medicine (2021)
Jinye Xie, Liang-Ping Xia, Wei Xiang, Wen-Zhuo He, Haofan Yin, Fang Wang, Tianxiao Gao, WeiWei Qi, Zhonghan Yang, Xia Yang, Ti Zhou, Guoquan Gao
Metformin selectively inhibits metastatic colorectal cancer with the KRAS mutation by intracellular accumulation through silencing MATE1. Proceedings of the National Academy of Sciences of the United States of America 117 (23) (2020)
Ri-Xin Chen, Xin Chen, Liang-Ping Xia, Jia-Xing Zhang, Zhi-Zhong Pan, Xiao-Dan Ma, Kai Han, Jie-Wei Chen, Jean-Gabrie Judde, Olivier Deas, Feng Wang, Ning-Fang Ma, Xinyuan Guan, Jing-Ping Yun, Feng-Wei Wang, Rui-Hua Xu, Dan Xie
N6-methyladenosine modification of circNSUN2 facilitates cytoplasmic export and stabilizes HMGA2 to promote colorectal liver metastasis. Nature communications 10 (1) (2019)